ADIPOQ and Insulin resistance: It is well known that circulating adiponectin increases insulin sensitivity [10], is decreased in T2D patients [10-13], and is negatively correlated with insulin resistance [22]; PPARγ agonists increase insulin sensitivity as well as circulating adiponectin [17,18].